Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer

Letrozole cut women's risk of recurrent or new tumors by more than half, study found

By Sherry Baker
HealthDay Reporter

TUESDAY, March 11 (HealthDay News) -- There's good news for the 60 percent of women with breast cancer whose malignancies are estrogen-driven: Researchers say taking the aromatase inhibitor (AI) drug letrozole (Femara) can cut risk of a recurrence by more than half.

That benefit was seen even when women initiated the drug one to seven years after they stopped treatment with the anti-estrogen drug tamoxifen, the study found.

Advertisement
Related Stories
 border=
New Screening Catches More Breast Cancers
Breast Cancer Drug Not Tied to Cognitive Decline: Study
Normal Cells May Predict Cancer Virulence
Related Videos
 border=
A Welcome Message from Survivor PJ Hamel
Smother Says "Cut!"
Maryann and Paula
Related Slides
 border=
Breast Cancer
Breast Self-Exam


In other findings, letrozole lowered the risk of breast cancer metastasis by 61 percent, according to the researchers. The drug also reduced the odds of a tumor forming in a breast that was initially cancer-free by more than 80 percent, said a team reporting in the April issue of the Journal of Clinical Oncology.

"We were expecting letrozole to work from the earlier, initial results, but the actual magnitude of benefit was a bit surprising. For any woman who has had hormone-sensitive breast cancer in the past, our results show a big reduction in recurrence if letrozole is initiated any time between 1 and 7 years after 5 years of tamoxifen -- that's up to 12 years after diagnosis," said lead researcher Dr. Paul E. Goss, director of Breast Cancer Research at Massachusetts General Hospital Cancer Center, Boston.

The findings are expected to be applied immediately to receptor-positive breast cancer treatment, Goss said.

There was one slight down side to letrozole therapy: Just over 5 percent of the 1,500 women taking the drug reported a new diagnosis of osteoporosis or bone fracture, compared to about 3 percent of 800 study participants who were not on the regimen, the researchers said.

Tamoxifen, which blocks estrogen receptor cells, is standard adjunct treatment for estrogen-sensitive cancers, but the benefits of the drug drop significantly after five years. Aromatase inhibitors block the other, less potent sources of estrogen in the body by keeping androgens from the adrenal glands and other tissues from transforming into estrogen.

The current study was based on data collected from the original MA.17 trial, conducted through the National Cancer Institute of Canada and also led by Goss. MA. 17 was designed to study whether letrozole could reduce tumor recurrence and increase survival in breast cancer patients after five years of tamoxifen treatment.

In October of 2003 , the study was ended a year earlier than originally planned when preliminary data showed that women taking letrozole were significantly less likely to have a cancer recurrence. Study participants in the placebo arm were offered letrozole when the study was halted. According to Goss, that gave the researchers the opportunity to compare the recurrence rates in women from the placebo group who chose to take the AI with those who decided on no further treatment.

Based on the new findings, "we believe every patient who has previously taken tamoxifen should discuss the findings of this study with her oncologist. Our results suggest if you take anti-estrogen, aromatase inhibitor therapy at any point of diagnosis, it is going to impact your chances of not experiencing a recurrence," Goss said.

Another expert agreed that the findings are significant.

"This study shows that the hormonal driving pathways continue to be very active after the tamoxifen has ended. And, the fact you've got a 60 percent improvement in disease-free survival with the addition of letrozole is a very powerful argument for its inclusion in treatment," said Dr. Brian Leyland-Jones, executive director of the Winship Cancer Institute at Emory University in Atlanta.

"The only imperfection of this trial, in terms of its design, is that it was not randomized -- patients chose whether or not to continue on letrozole," Leyland-Jones said. "And the only negative note is the risk of osteoporosis and increased risk of fractures for those who switched to letrozole. So, the news is very good but not all perfect."

More information

For more on breast cancer, head to the National Cancer Institute.

SOURCES: Paul E. Goss, M.D, Ph.D., director, Breast Cancer Research, Massachusetts General Hospital Cancer Center, Boston; Brian Leyland-Jones, M.D., Ph.D., executive director, Winship Cancer Institute, Emory University, Atlanta; April 2008, Journal of Clinical Oncology

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 3/11/2008



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Sep 5, 2008
Home
Search
Powered By HealthLine
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: